Feeds:
Posts
Comments

Archive for the ‘Artificial Intelligence Applications in Health Care’ Category

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session  October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:40 – 2:30

AI in Precision Medicine

Dr. Ganhui Lan
Dr. Xiaoyan Wang
Dr. Ahmad P. Tafti
Jen Gilburg

Jen Gilburg (moderator)Deputy Secretary of Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

  • AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
  • Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
  • nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
  • Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
  • Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
  • 95% of AI projects not successful because most projects are very discrete use

2:00-2:20

Building Precision Oncology Infrastructure in Low- and Middle-Income Countries

Razelle Kurzrock, MD

Sewanti Limaye, MD, Director, Medical & Precision Oncology; Director Clinical and Translational Oncology Research, Sir HN Reliance Foundation Hospital & Research Centre, Mumbai, India; Founder, Nova Precision AI; Co-Founder, Iylon Precision Oncology; Co-Chair, Asia Pacific Coalition Against Lung Cancer; Co-Chair,  Asia Pacific Immuno-Oncology; Member,  WIN Consortium

  • globally 60 precision initiatives but there really are because many in small countries
  • three out of five individuals in India die of cancer
  • precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
  • in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
  • prevention is always a difficult task in LMICs (low income)
  • you have ten times more patients in India than in US (triage can be insurmountable)
  • ICGA Foundation: Indian Cancer Genome Atlas
  • in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
  • genomic landscape of ovarian cancer in India totally different than in TCGA data
  • even different pathways are altered in ovarian cancer seen in North America than in India
  • MAY mean that biomarker panels need to be adjusted based on countries used in
  • the molecular data has to be curated for the India cases to be submitted to a tumor board
  • twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
  • they are also tailoring diagnostic and treatment for India getting FDA fast track approvals

2:20-2:40

Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors

Razelle Kurzrock, MD

Lori Rink, PhD, Associate ProfessorFox Chase Cancer Center

  • GIST are most common nesychymal tumor in GI tract
  • used to be misdiagnosed; was considered a leimyosarcoma
  • very asymptomatic tumors and not good prognosis
  • very refractory to genotoxic therapies
  • RTK KIT/PDGFRA gain of function mutations
  • Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
  • there is a mutation map for hotspot mutations and sensitivity for gleevec
  • however resistance emerged to ripretinib; in ATP binding pocket
  • over treatment get a polyclonal resistance
  • performed a kinome analysis; Wee1 looked like a potential target
  • mouse studies (80 day) showed good efficacy
  • avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
  • but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
  • cotargeting KIT/PDGFRA and WEE1 increases replicative stress
  • they are using PDX models to test these combinations
  • combination creates genomic instability

 

Read Full Post »

Advances in Liver Transplantation: New Frontiers in Organ Regeneration and Immunomodulation

Curator: Dr. Sudipta Saha, Ph. D.

 

Recent research in the field of liver transplantation has been marked by significant advancements in organ preservation, immune tolerance, and regenerative medicine. Efforts have been made to address the critical shortage of donor organs and reduce long-term complications associated with immunosuppressive therapy.

Normothermic machine perfusion (NMP) techniques have been employed to preserve and assess donor livers outside the body. This method has allowed marginal or extended criteria livers to be reconditioned, increasing the usable donor pool. The viability of these organs has been improved through real-time functional monitoring during perfusion.

Immunological tolerance has been targeted through cell-based therapies and gene editing strategies. Regulatory T-cell therapies and tolerogenic dendritic cells have been investigated to reduce the reliance on lifelong immunosuppression. CRISPR-based gene editing is also being explored to modify donor tissues before transplantation to evade host immune responses.

In parallel, liver organoids and bioengineered tissue scaffolds have been studied for their potential in partial transplantation or functional support in acute liver failure. Although clinical application remains at an early stage, these developments have suggested future directions for transplant alternatives or bridge-to-transplant therapies.

Artificial intelligence has been integrated into transplant decision-making, predicting post-transplant outcomes and optimizing donor-recipient matching. These models are being trained on large datasets to improve prognostic accuracy.

Ethical concerns surrounding organ allocation equity and experimental treatments continue to be actively discussed. However, these advancements have collectively pushed the boundaries of transplant medicine toward safer, more personalized, and more sustainable outcomes.

References:

https://pubmed.ncbi.nlm.nih.gov/29670285

https://pubmed.ncbi.nlm.nih.gov/32976865

https://pubmed.ncbi.nlm.nih.gov/32546694

https://pubmed.ncbi.nlm.nih.gov/31954498

Read Full Post »

Tirzepatide Outperforms Semaglutide in Diabetes Control

Curator: Dr. Sudipta Saha, Ph. D.

In a recent clinical study published in The New England Journal of Medicine, the effectiveness of tirzepatide was compared with that of semaglutide in patients with type 2 diabetes. The trial was conducted to evaluate which of the two medications offers better glycemic control and weight loss benefits when combined with standard care.

It was found that participants treated with tirzepatide achieved significantly greater reductions in both HbA1c levels and body weight than those who received semaglutide. A once-weekly administration of tirzepatide was shown to be more effective across multiple dosages. These findings were consistent even in patients with longstanding diabetes and those previously treated with insulin or oral agents.

Gastrointestinal side effects were commonly observed in both groups, including nausea and diarrhoea, but were generally mild to moderate in severity. No new safety concerns were identified during the study period.

The enhanced dual agonist mechanism of tirzepatide, which targets both GIP and GLP-1 receptors, is believed to have contributed to its superior efficacy. While semaglutide acts only on the GLP-1 pathway, tirzepatide’s dual action is thought to improve insulin sensitivity, promote satiety, and reduce appetite more robustly.

This trial represents a significant advancement in diabetes care and suggests that tirzepatide may become a preferred treatment option in clinical practice. It has been proposed that future studies investigate its long-term cardiovascular effects, impact on diabetic complications, and cost-effectiveness in diverse populations.

References:

https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

https://www.sciencedirect.com/science/article/pii/S154235652400226X

https://pubmed.ncbi.nlm.nih.gov/29364588

https://pubmed.ncbi.nlm.nih.gov/29364588

https://www.who.int/publications/i/item/9789241565257

Read Full Post »

Sleeping Threats: Immune System’s Watch on Dormant Cancer

Curator: Dr. Sudipta Saha, Ph. D.

 

The immune system’s role in regulating dormant cancer cells has been increasingly elucidated, revealing a complex interplay that influences metastasis and cancer recurrence. Dormant cells, which enter a non-proliferative state, can evade immune detection and remain quiescent for prolonged periods.


Mechanisms of immune evasion include down-regulation of antigen presentation and residence within immune-privileged niches such as bone marrow. Both innate and adaptive immunity, particularly CD8+ T cells and natural killer cells, are involved in maintaining dormancy and preventing metastatic outgrowth.


Micro-environmental factors that modulate immune surveillance and dormancy status have been identified. Changes in cytokine profiles and inflammation can disrupt dormancy, leading to cancer cell reactivation and metastasis.


Therapeutic approaches to sustain dormancy or eliminate dormant cells are under development. These include immune checkpoint inhibitors, cancer vaccines, and cytokine modulators aimed at enhancing immune recognition and clearance.


By targeting dormant cancer cells through immune modulation, it is anticipated that metastasis can be delayed or prevented, significantly improving long-term patient outcomes and reducing cancer mortality.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastasis-dormant-cancer-cells-immune-system

https://www.nature.com/articles/nrc2256

https://pubmed.ncbi.nlm.nih.gov/33681821/

https://pubmed.ncbi.nlm.nih.gov/33811127/

https://www.nature.com/articles/nrc3910

https://pubmed.ncbi.nlm.nih.gov/27015306

 

Read Full Post »

Bridging the Gender Gap in Healthcare: Unlocking Biopharma’s Potential in Women’s Health

Curator: Dr. Sudipta Saha, Ph.D.

Nearly half of the global population—and 80 percent of patients in therapeutic areas such as immunology—are women. Yet, treatments are frequently developed without tailored insights for female patients, often ignoring critical biological differences such as hormonal impacts, genetic factors, and cellular sex. Historically, women’s health has been narrowly defined through the lens of reproductive organs, while for non-reproductive conditions, women were treated as “small men.” This lack of focus on sex-specific biology has contributed to significant gaps in healthcare.

A recent analysis found that women spend 25 percent more of their lives in poor health compared with men due to the absence of sex-based treatments. Addressing this disparity could not only improve women’s quality of life but also unlock over $1 trillion in annual global GDP by 2040.

Four key factors contribute to the women’s health gap: limited understanding of sex-based biological differences, healthcare systems designed around male physiology, incomplete data that underestimates women’s disease burden, and chronic underfunding of female-focused research. For instance, despite women representing 78 percent of U.S. rheumatoid arthritis patients, only 7 percent of related NIH funding in 2019 targeted female-specific studies.

However, change is happening. Companies have demonstrated how targeted R&D can drive better outcomes for women. These therapies achieved expanded FDA approvals after clinical trials revealed their unique benefits for female patients. Similarly, addressing sex-based treatment gaps in asthma, atrial fibrillation, and tuberculosis could prevent millions of disability-adjusted life years.

By closing the women’s health gap, biopharma companies can drive innovation, improve therapeutic outcomes, and build high-growth markets while addressing long-standing inequities. This untapped opportunity holds the potential to transform global health outcomes for women and create a more equitable future.

References

https://www.mckinsey.com/industries/life-sciences/our-insights/closing-the-womens-health-gap-biopharmas-untapped-opportunity?stcr=97136BA6BDD64C2396A57E9487438CC6

https://www.weforum.org

https://www.nih.gov

https://www.fda.gov

https://www.who.int

Read Full Post »

DeepSeek-V3 and Reasoning Model R1: Four Views (a) Explanations (b) The Chinese Perspective (c) DeepSeek Impact on Demand for Inference Chips & Training Chips, and (d) LPBI Group: Expert Content for ML Models in Healthcare, Pharmaceutical, Medical and Life Sciences

Curator: Aviva Lev-Ari, PhD, RN

With the announcement of DeepSeek on January 27, 2025, it became compelling to cover several aspects of this hot Artificial Intelligence Technology.

This curation has four Parts: 

Part A: Explanations 

Part B: The Chinese Perspective

Part C: DeepSeek potential Impact on Demand for Inference Chips & Training Chips, and

Part D: LPBI Group: Expert Content for ML Models in Healthcare, Pharmaceutical, Medical and Life Sciences

 

Part A: Explanations by Morgan Brown

@morganb

Jan 27   Read on X

🧵 Finally had a chance to dig into DeepSeek’s r1…

Let me break down why DeepSeek’s  AI innovations are blowing people’s minds (and possibly threatening Nvidia’s $2T market cap) in simple terms… 

0/ first off, shout out to @doodlestein who wrote the must-read on this here:

The Short Case for Nvidia StockAll the reasons why Nvidia will have a very hard time living up to the currently lofty expectations of the market.https://youtubetranscriptoptimizer.com/blog/05_the_short_case_for_nvda

1/ First, some context: Right now, training top AI models is INSANELY expensive. OpenAI, Anthropic, etc. spend $100M+ just on compute. They need massive data centers with thousands of $40K GPUs. It’s like needing a whole power plant to run a factory. 

2/ DeepSeek just showed up and said “LOL what if we did this for $5M instead?” And they didn’t just talk – they actually DID it. Their models match or beat GPT-4 and Claude on many tasks. The AI world is (as my teenagers say) shook. 

3/ How? They rethought everything from the ground up. Traditional AI is like writing every number with 32 decimal places. DeepSeek was like “what if we just used 8? It’s still accurate enough!” Boom – 75% less memory needed. 

4/ Then there’s their “multi-token” system. Normal AI reads like a first-grader: “The… cat… sat…” DeepSeek reads in whole phrases at once. 2x faster, 90% as accurate. When you’re processing billions of words, this MATTERS. 

5/ But here’s the really clever bit: They built an “expert system.” Instead of one massive AI trying to know everything (like having one person be a doctor, lawyer, AND engineer), they have specialized experts that only wake up when needed.

[color added by curator, See Part D, below]

6/ Traditional models? All 1.8 trillion parameters active ALL THE TIME. DeepSeek? 671B total but only 37B active at once. It’s like having a huge team but only calling in the experts you actually need for each task. 

7/ The results are mind-blowing:
– Training cost: $100M → $5M
– GPUs needed: 100,000 → 2,000
– API costs: 95% cheaper
– Can run on gaming GPUs instead of data center hardware 

8/ “But wait,” you might say, “there must be a catch!” That’s the wild part – it’s all open source. Anyone can check their work. The code is public. The technical papers explain everything. It’s not magic, just incredibly clever engineering. 

9/ Why does this matter? Because it breaks the model of “only huge tech companies can play in AI.” You don’t need a billion-dollar data center anymore. A few good GPUs might do it. 

10/ For Nvidia, this is scary. Their entire business model is built on selling super expensive GPUs with 90% margins. If everyone can suddenly do AI with regular gaming GPUs… well, you see the problem. 

11/ And here’s the kicker: DeepSeek did this with a team of <200 people. Meanwhile, Meta has teams where the compensation alone exceeds DeepSeek’s entire training budget… and their models aren’t as good. 

12/ This is a classic disruption story: Incumbents optimize existing processes, while disruptors rethink the fundamental approach. DeepSeek asked “what if we just did this smarter instead of throwing more hardware at it?” 

13/ The implications are huge:
– AI development becomes more accessible
– Competition increases dramatically
– The “moats” of big tech companies look more like puddles
– Hardware requirements (and costs) plummet 

14/ Of course, giants like OpenAI and Anthropic won’t stand still. They’re probably already implementing these innovations. But the efficiency genie is out of the bottle – there’s no going back to the “just throw more GPUs at it” approach. 

15/ Final thought: This feels like one of those moments we’ll look back on as an inflection point. Like when PCs made mainframes less relevant, or when cloud computing changed everything.

 AI is about to become a lot more accessible, and a lot less expensive. The question isn’t if this will disrupt the current players, but how fast.

/end 

P.S. And yes, all this is available open source. You can literally try their models right now. We’re living in wild times! 🚀 

Momma, I’m going viral! No substack or gofundme to share but a few things to add/clarify:

1/ The DeepSeek app is not the same thing as the model. Apps are owned and operated by a Chinese corporation, the model itself is open source.

2/ Jevon’s paradox is the counter argument. Thanks papa @satyanadella. Could be a mix shift in chip type, compute type, etc. but we’re constrained by power and compute right now, not demand constrained.

3/ The techniques used are not ground breaking. It’s the combination of them w/the relative model performance that is so exciting. These are common eng techniques that combined really fly in the face of more compute is the only answer for model performance. Compute is no longer a moat.

4/ Thanks to all for pointing out my NVIDIA market cap numbers miss and other nuances – will do better next time, coach. 🫡 

SOURCE

https://threadreaderapp.com/thread/1883686162709295541.html#google_vignette

 

Part B: The Chinese Perspective

© 2025 Jordan Schneider

DeepSeek: The View from China

China’s takes are better than yours

 

SOURCE

From: ChinaTalk <chinatalk@substack.com> on behalf of ChinaTalk <chinatalk@substack.com>
Reply-To: ChinaTalk <reply+2ktto4&8t4ds&&6fa8442469b96573268378f7538ff49c28c45589f5811b2a55b30e89ee8ff94d@mg1.substack.com>
Date: Tuesday, January 28, 2025 at 9:54 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: DeepSeek: The View from China

And

https://www.chinatalk.media/p/deepseek-the-view-from-china

https://open.substack.com/pub/chinatalk/p/deepseek-the-view-from-china?r=8t4ds&utm_campaign=post&utm_medium=email

The Mystical DeepSeek. ‘The most important thing about DeepSeek is pushing intelligence’

  1. Founder and CEO Liang Wenfeng is the core person of DeepSeek. He is not the same type of person as Sam Altman. He is very knowledgeable about technology.
  2. DeepSeek has a good reputation because it was the first to release the reproducible MoE, o1, etc. It succeeded in acting early, but whether or not it did the absolute best remains to be seen. Moving forward, the biggest challenges are that resources are limited and can only be invested in the most high-potential areas. DeepSeek’s research and culture are still strong, and if given 100,000 or 200,000 chips, they might be able to do better.
  3. From its preview to its official release, DeepSeek’s model’s long-context capabilities have improved rapidly. DeepSeek’s long-context 20K can be achieved with very conventional methods.
  4. The CEO of Scale.ai said that DeepSeek has 50,000 chips, but that is definitely not reality. According to public information, DeepSeek had 10,000 old A100 chips and possibly 3,000 H800 cards before the ban. DeepSeek pays great attention to compliance and has not purchased any non-compliant GPUs, so it should have few chips. The way the United States uses GPUs is too extravagant.
  5. DeepSeek focused all its efforts on a single goal and subsequently gave up many things, such as multimodality. DeepSeek is not just serving people, but seeking intelligence itself, which may have been a key factor in its success.
  6. In some ways, quant trading can be said to be the business model of DeepSeek. Huanfang (another quantitative investment company founded by Liang Wenfeng) is the product of the last round of machine learning. DeepSeek’s highest priority is to push intelligence. Money and commercialization are not high priorities. China needs several leading AI labs to explore things that can beat OpenAI. Intelligence takes a long time to develop, and has begun to differentiate again this year, so new innovations are bound to result.
  7. From a technical perspective, DeepSeek has been instrumental as a training ground for talent.
  8. The business model of AI labs in the United States is not good either. AI does not have a good business model today and will require viable solutions in the future. Liang Wenfeng is ambitious; DeepSeek does not care about the model and is just heading towards AGI.
  9. Many of the insights from DeepSeek’s paper involve saving hardware costs. On a couple of big dimensions of scaling, DeepSeek’s techniques are able to reduce costs.
  10. In the short-term, everyone will be driven to think about how to make AI more efficient. In the long-run, questions about computing power will remain. Demand for compute remains strong and no company has enough.
  11. Discussing DeepSeek’s organization:
    1. When investing, we always choose the most advanced talent. But we see from DeepSeek’s model (the team is mostly smart young people who graduated from domestic universities) that a group that coheres well may also gradually advance their skills together. It has yet to be seen whether poaching one person might break DeepSeek’s advantage, but for now this seems unlikely.
    2. While there’s a lot of money in the market, DeepSeek’s core advantage is its culture. The research culture of DeepSeek and ByteDance are similar, and both are critical for determining the availability of funding and long-term viability. Only with an important business model can there be a sustainable culture. Both DeepSeek and ByteDance have very good business models.
  12. Why did DeepSeek catch up so fast?
    1. Reasoning models require high-quality data and training. For LLMs or multimodal AI, it’s difficult to catch up with a closed source model from scratch. The architecture of pure reasoning models hasn’t changed much, so it’s easier to catch up in reasoning.
    2. One reason R1 caught up quickly was that the task was not particularly difficult. Reinforcement learning only made the model choices more accurate. R1 did not break through the efficiency of Consensus 32, spending 32 times the efficiency, which is equivalent to moving from deep processing to parallelization, which is not pushing the boundaries of intelligence, just making it easier.

Pioneers vs. Chasers: ‘AI Progress Resembles a Step Function – Chasers Require 1/10th the Compute’

Points 13 – 17

[Points 18-48 was a long technical discussion we’ve machine-translated below]

Why didn’t the other companies take the DeepSeek approach: ‘Models from the big labs need to maintain a low profile’

Points 49, 50

The Divergence and Bets of 2025 Technology: ‘Can We Find Architectures Beyond Transformer?’

Points 51 – 56

Have developers moved from closed-source models to DeepSeek? ‘Not yet’

Points 57 – 62

OpenAI Stargate’s $500B Narrative and Changes in Computing Power Demand

  1. The emergence of DeepSeek has led people to question the latest $500B narrative from Nvidia and OpenAI. There’s no verdict yet on compute — and OpenAI’s $500B narrative is their attempt to throw themselves a lifeline.
  2. Regarding the doubts about OpenAI’s $500B infrastructure investment: because OpenAI is a commercial company, it could be risky if debt is involved.
  3. $500B is an extreme number — likely to be executed over 4 or 5 years. SoftBank and OpenAI are the leading players (the former providing capital, the latter technology) — but SoftBank’s current funds can’t support $500B; rather SoftBank is using its assets as collateral. OpenAI, meanwhile, isn’t very cash-rich either, and other AI companies are more technical participants than they are funding providers. So it will be a struggle to fully realize the $500B vision.
  4. OpenAI’s $500B computing power makes sense: during the exploration phase, the cost of trial and error is high, with both human and investment costs being substantial. But although the path isn’t clear and getting from o1 to R1 won’t be easy, at least we can see what the finish line looks like: we can track the intermediate markers, and from day one, aim for others’ proven end states; this gives us a better bearing on our progress. Being at the frontier exploring the next generation is most resource-intensive. The followers don’t bear exploration costs — they’re always just following. If Google/Anthropic succeed in their exploration areas, they might become the frontier company.
  5. In the future, Anthropic might replace all their inference with TPU or AWS chips.
  6. Domestic Chinese companies were previously constrained by computing power, but now it’s proven that the potential technical space is vast. For more efficient models, we might not need especially large cards — we can provide relatively customized chips that can be adapted for compatibility with AMD and ASIC. From an investment perspective, Nvidia’s moat is very high, but ASIC will have yet greater opportunities.
  7. The DeepSeek situation isn’t really about compute — it’s about America realizing China’s capabilities and efficiency.DeepSeek isn’t Nvidia’s vulnerability; Nvidia will grow as long as AI grows. Nvidia’s strength is its ecosystem, which has been built up over a long time. Indeed, when technology develops rapidly, the ecosystem is crucial. The real crisis comes, though, when technology matures like electricity: it becomes commoditized; then, everyone will focus on products, and many ASIC chips will emerge for specific scenario optimization.

 

Impact on the Secondary Market: ‘Short-term sentiment is under pressure, but the long-term narrative continues’

Points 70 – 74

Open-Source vs Closed Source: ‘If capabilities are similar, closed source will struggle.’

Points 75 – 78

The Impact of DeepSeek’s Breakthrough: ‘Vision Trumps Technology’

  1. DeepSeek’s breakthrough made the outside world realize China’s AI strength. Previously, outsiders thought China’s AI progress lagged America by two years, but DeepSeek shows the gap is actually 3 to 9 months, and in some areas, even shorter.
  2. When it comes to technologies and sectors that America has historically blocked China from accessing, if China can break through nonetheless, those sectors ultimately become highly competitive. AI might follow this pattern — and DeepSeek’s success may well prove this.
  3. DeepSeek didn’t suddenly explode. R1’s impressive results reverberated throughout America’s entire AI establishment.
  4. DeepSeek stands on the shoulders of giants — but exploring the frontier still requires much more time and human capital cost. R1 doesn’t mean that future training costs will decrease.
  5. AI explorers definitely need more computing power; China, as a follower, can leverage its engineering advantages. How Chinese large-model teams use less computing power to produce results, thereby having some definite resilience — or even doing better — might end up being how the US-China AI landscape plays out in the future.
  6. China is still replicating technical solutions; reasoning was proposed by OpenAI in o1, so the next gap between various AI labs will be about who can propose the next reasoning. Infinite-length reasoning might be one vision.
  7. The core difference between different AI labs’ models lies not in technology, but in what each lab’s next vision is.
  8. After all, vision matters more than technology.

Technical Discussion

There was a deep technical discussion in the article that we’ve machine-translated below.

Technical Detail 1: Supervised Fine-Tuning (SFT). ‘No need for SFT on the reasoning level’

Points 18 – 27

Technical Detail 2: Data. ‘DeepSeek values data annotation’

Points 28 – 30

Technical Detail 3: Distillation. ‘The limit of distillation is that model diversity drops

Points 31 – 43

Technical Detail 4: Process Reward. ‘The upper limit of process reward is human, but the upper limit of outcome supervision is the model itself.’

Points 44 – 48

 

SOURCE of the Chinese Perspective

https://www.chinatalk.media/p/deepseek-the-view-from-china?utm_source=substack&publication_id=4220&post_id=155916148&utm_medium=email&utm_content=share&utm_campaign=email-share&triggerShare=true&isFreemail=true&r=8t4ds&triedRedirect=true

 

Part C: DeepSeek Impact on Demand for “Inference Chips” and “Training Chips”

 

Watch Full Interviews with Ark’s Cathie Wood

 

  • Ark’s Wood on DeepSeek, AI, Crypto, Trump | Cathie Wood Full Interview

https://youtu.be/EKELCEW8lNo?si=Zri9QqcMHsESgO8N

 

  • Cathie Wood Talks DeepSeek Lessons, Musk, Driverless Cars & UK

https://youtu.be/aThejSuMX-I?si=e9uM7TpoQ1Neb-cT

 

“Inference Chips” and “Training Chips”: Technology explained

 

AI Chips Explained: Training vs. Inference Processors Unveiled

https://www.friendsofthemetaverse.com/blog/ai-chips-explained-training-vs-inference-processors-unveiled

 

Inference chips and training chips are both types of AI chips that serve different purposes. Training chips are used to develop AI models, while inference chips are used to deploy those models in real-world applications. 

An “inference chip” is designed to efficiently execute a trained AI model on new data to make predictions in real-time, prioritizing low latency and power consumption, while a “training chip” is optimized for the computationally intensive process of initially training a machine learning model, requiring high processing power and memory bandwidth, often at the cost of power efficiency; essentially, inference chips are for “applying” the learned model, while training chips are for “learning” the model itself. 

 

SOURCE

https://www.google.com/search?q=training+chips+vs+inference+chips&oq=Training+Chips+vs+Inference+chips&gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7Mg0IARAAGIYDGIAEGIoFMg0IAhAAGIYDGIAEGIoFMg0IAxAAGIYDGIAEGIoFMgoIBBAAGIAEGKIEMgoIBRAAGIAEGKIEMgoIBhAAGIAEGKIEMgoIBxAAGIAEGKIE0gEKMTc2OTVqMGoxNagCCLACAQ&sourceid=chrome&ie=UTF-8

 

Training vs. Inference (But, Really: Training Then Inference)

To recap: the AI training stage is when you feed data into your learning algorithm to produce a model, and the AI inference stage is when your  algorithm uses that training to make inferences from data. Here’s a chart for quick reference: 

Table

Inference

Feed training data into a learning algorithm

Apply the model to the inference data

Produces a model comprising code and data

Produces output data

One time-ish (Requirement to retain training data in case of re-training.)

Often continuous

Inference

Apply the model to the inference data

Produces output data

Often continuous

The difference may seem inconsequential at first glance, but defining these two stages helps to show implications for AI adoption particularly with businesses. That is, given that it’s much less resource intensive (and therefore, less expensive), it’s likely to be much easier for businesses to integrate already-trained AI algorithms with their existing systems. 

And, as always, we’re big believers in demystifying terminology for discussion purposes. Let us know what you think in the comments, and feel free to let us know what you’re interested in learning about next.

SOURCE

AI 101: Training vs. Inference

November 9, 2023 by Stephanie Doyle

https://www.backblaze.com/blog/ai-101-training-vs-inference/

 

r/AMD_Stock

“AI is really two markets, training and inference. Inference is going to be 100 times bigger than training. Nvidia is really good at training but very miscast at inference.” – Chamath Palihapitiya

Let’s discuss.

Below I layout AMD investor relevant time stamps:

7:35 – Meta AI business strategy

10:00 – Open source impact on LLM marketplace

12:10 – Telecom analogy (capex discussion)

16:35 – Closed source model economic viability

19:50 – Meta overspend on training (Nvidia)

SOURCE

https://www.reddit.com/r/AMD_Stock/comments/1cf765y/ai_is_really_two_markets_training_and_inference/

 

Part D: LPBI Group: Expert Content for ML Models in Healthcare, Pharmaceutical, Medical and Life Sciences

 

LPBI Group’s Journal http://pharmaceuticalintelligence.com had a fully developed ontology for the Healthcare, Pharmaceutical, Medical and Life Sciences domains of knowledge.

The ontology comprises of +750 categories of research. Each category consists of multiple scientific articles that were curated by domain knowledge experts in the fields of Healthcare, Pharmaceutical, Medical and Life Sciences.

  • Each article is a token, a Non Fungible Token (NFT) = a mutually exclusive scientifically written piece that makes a Prior Art artifact from the intellectual property law perspective and copyright law.
  • Each category of research is “An expert system knowledge base”
  • Examples: The last column in this table represents the number of articles in this category of research
  • Each curation is written by an expert in this domain, and
  • Each one of the 469 articles in Example #1, in this category of research had been assigned THIS category by an EXPERT in this domain. 
  • The universe of 469 articles represents an “Expert System Knowledge Base” in the domain of biological networks, gene regulation and evolution
  • Example #1 comprises of 469 NFTs
  • Example #2 comprises of 1,022 NFTs
  • Example #3 comprises of 681 NFTs
  • An ML model can be trained on the content of a Master file that included the content of all the 469 article files mentioned in Example #1 – that process is performed on Training Chips
  • The outcomes of the model involve the phase of Inference. That process is performed on Inference Chips.

 

Example #1: 469 articles in Biological Networks, Gene Regulation and Evolution

Expert, Author, Writer (EAW): Dr. Larry Bernstein
Degree: BS, MS, MD
Specialty: Clinical Pathology
e-Mail: larry.bernstein@gmail

N = 469

Biological Networks, Gene Regulation and Evolution

 

Points (a) to (f) are applicable as well to Example #2, and #3, below. Or for any other category of research from the universe of +750 categories that consists of +50 articles

 

Example #2: 1,022 articles in CANCER BIOLOGY & Innovations in Cancer Therapy

Contributor EAW: Prabodh kumar Kandala, PhD Specialty: Preclinical Oncology, Prabodh.kandala@gmail.com

Contributor EAW: Ritu Saxena, PhD
ritu.uab@gmail.com

Contributor EAW: Dr. Larry Bernstein
Degree: BS, MS, MD
Specialty: Clinical Pathology
e-Mail: larry.bernstein@gmail.com

Contributor EAW: Stephen J. Williams
Degree: Ph.D. Pharmacology
Specialty: cancer pharmacology, ovarian specialty
e-Mail: sjwilliamspa@comcast.net
Phone: 215-487-0259

Contributor EAW: Tilda Barliya
Degree: PhD
Specialty: Cancer biology, cell biology, nanotechnology and drug delivery
e-Mail: tildabarliya@gmail.com
Phone: +972-50-8622289

N = 1,022

CANCER BIOLOGY & Innovations in Cancer Therapy

 

Example #3: 681 articles in Frontiers in Cardiology and Cardiovascular Disorders

EAW: Aviva Lev-Ari, PhD, RN

EAW: Justin D. Pearlman
Degree: MD ME PhD MA FACC
Specialty: Internal Medicine, Cardiology, Cardiovascular Radiology, Image Processing, Computer Science, Electronic Records
jdpmdphd@gmail.com
Phone:617-894-6888

N = 681

Frontiers in Cardiology and Cardiovascular Disorders

 

Respectively, the categories of research are

  • “Expert systems domain knowledge bases”
  • They are ready for ML model development in each of the domains that a category comprises more than 50 articles.
  • Total number of categories of research in the Journal’s Ontology N = 757 on 1/28/2025

Read Full Post »

SNU-BioTalk 2025: Symphony of Cellular Signals in Metabolism and Immune Response – International Conference at Sister Nivedita University, Kolkata, India on 16 & 17 January 2025

SNU-BioTalk 2025: Symphony of Cellular Signals in Metabolism and Immune Response – International Conference at Sister Nivedita University, Kolkata, India on 16 & 17 January 2025

Joint Convenor: Dr. Sudipta Saha (Member of LPBI since 2012)

About the Conference:

The International Conference on ‘Symphony of Cellular Signals in Metabolism and Immune Response’ focuses on the complex signalling pathways governing cellular functions in health and disease. It will explore the cellular mechanisms that regulate metabolism, immune responses, and survival, highlighting advances in medical science and biotechnology. Bringing together leading experts and emerging researchers, the conference will feature keynote lectures, panel discussions, research presentations, and interactive sessions, all designed to foster collaboration and innovation. By promoting an exchange of ideas, the event aims to drive transformative insights and solutions that impact human health and sustainable healthcare practices.

The conference will also be livestreamed on YouTube and Facebook

This programme will also host I-STEM: Indian Science, Technology and Engineering facilities Map (I-STEM) is a dynamic and interactive national portal for research cooperation.

Thrust areas:

  • Intracellular signalling processes of cellular metabolism
  • Signalling pathways in physiological and pathological processes
  • Signalling in innate and adaptive immunity

Conference Webpage: https://www.snuniv.ac.in/snu-biotalk-2025/

NU-BioTalk 2025 Abstract Submission Form: https://forms.gle/ygdGqtuBGa7DEhDFA

SNU-BioTalk 2025 Registration Form: https://forms.gle/unasPpByLmYwrRBM6

Programme Schedule:

YouTube Links of Live Telecast:

Day 1:

Day 2:

Media:

Newspaper:

The Telegraph – Click to View

 

Abstract Book

Scan to Download:

Click: 

Abstract Book

Read Full Post »

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 2 2024

Reporter: Stephen J. Williams, Ph.D.

9:20-9:50

How Can We Close the Clinical Practice Gaps in Precision Medicine?

Susanne Munksted, Diaceutics

Studies are showing that genetic tests are being ordered at a sufficient rate however it appears there are problems in interpretation and developing treatment plans based on omics testing results

 

  • 30 % of patients in past and now currently half of all patients are not being given the proper treatment based on genomic testing results (ASCO)
  • E.g. only 1.5% with NTRK fusions received a NTRK based therapy (this was > 4000 patients receiving wrong therapy)
  • A lung oncologist may only see one patient with NTRK fusion in three years

 

Precision Medicine Practice Gaps

48% of oncologist surveyed  agreed pathologist needs to be more informed and relevant in the decision making process with regard to tests needing to be ordered

95% said need to flip cost issues ; what does it cost not to get a test … i.e. what is the cost of the wrong therapy

We need a new commercialization model for therapeutic development for this new era of “n of one” patient

9:50-10:15

Implementation of a CLIA-based Reverse Phase Protein Array Assay for Precision Oncology Applications: Proteomics and Phosphoproteomics at the Bedside (CME Eligible)

Emanuel Petricoin, George Mason University

There are some tumor markers approved by FDA that cant just be measured by NGS and are correlated with a pathologic complete response

 

  • Many point mutations will have no actionable drug
  • Many alterations are post-genomic meaning there is a post translational component to many prognostic biomarkers
  • Prevalence of point mutation with no actionable mutation is a limit of NGS
  • It is important to look at phospho protein spectrum as a potential biomarker

 

Reverse phase protein proteomic analysis

  • Made into CLIA based array
  • They trained centers around the US on the technology and analysis
  • Basing proteomics or protein markers by traditional IHC requires much antibody validation so if the mass spectrometry field can catch up it would be very powerful
  • With multiple MRM.MS there is too low abundance of phosphoproteins to allow for good detection

 

They  conducted the I-SPY2 trial for breast cancer and determining if phosphoproteins could be a good biomarker panel

  • They found they could predict a HER2 response better than NGS
  • There were patients who were predicted HER2 negative that actually had an activated HER2 signaling pathway by proteomics so NGS must have had a series of false negatives
  • HER2 co phosphorylation predicts pathologic complete response and predicts therapy by herceptin
  • They found patients classified as HER2 negative by FISH were HER2 positive by proteomics and had HER2 activation

10:15-11:10

Liquid Biopsy MRD to Escalate or De-escalate Therapy (CME Eligible)

Adrian Lee

Adrian Lee, UPMC

Marija Balic, UPMC

Howard McLeod

Howard McLeod, Utah Tech University

Muhammed, Murtaza, University of Wisconsin-Madison

 

11:15-11:25  PRODUCT PRESENTATION  204A

SpaceIQ™ – Powering Next Generation Precision Therapeutics with AI-Driven Spatial Biomarkers

Dusty Majumdar, PredxBio 

Single Cell and Spatial Omics

 

  • Single cell transcriptomics technology have been scaled up very nicely over the past ten years
  • Spatial informatics field is lacking in innovations
  • Can get a terabyte worth of data from analysis of one slide

11:25-11:35  PRODUCT PRESENTATION  204C

10x Genomics

11:40-12:35

Transcriptomics and AI in Transforming Precision Diagnosis

Maher Albitar, Genomic Testing Cooperative

Transciptomica and AI:Transforming Precision diagnosis

-The Genomics Testing Coopererative at www.genomictestingcooperative.com

 

Advantages of transcriptomics

– mutation frequency and allele variant detection now at 80% (higher sensitivity in mutation detection)

 

– transcriptomics has good detection of chromosomal translocations

– great surrogate for IHC and detect splicing alterations

– can use AI to predict % of PDL1 in tumor cells versus immune cells

– they have developed a software UMAP (uniform manifold approximation and projection) to supervise cluster analysis

– the group has used AI to predict prognosis and survival using transcriptomics data

Marija Balic, UPMC

Andrew Pecora, Hackensack University Medical Center 

12:35-1:00

The Impact of Multi-Omics in the Context of the APOLLO-2 Moonshot Program (CME Eligible)

 

 

Read Full Post »

Coverage Afternoon Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

Reporter: Stephen J. Williams, Ph.D.

Unlocking the Next Quantum Leap in Precision Medicine – A Town Hall Discussion (CME Eligible)

Co-Chairs

Amanda Paulovich, Professor, Aven Foundation Endowed Chair
Fred Hutchinson Cancer Center

Susan Monarezm Deputy Director ARPA-H

Henry Rodriguez, NCI/NIH

Eric Schadt, Pathos

Ezra Cohen, Tempus

Jennifer Leib, Innovation Policy Solutions

Nick Seddon, Optum Genomics

Giselle Sholler, Penn State Hershey Children’s Hospital

Janet Woodcock, formerly FDA

Amanda Paulovich: Frustrated by the variability in cancer therapy results.  Decided to help improve cancer diagnostics

  •  We have plateaued on relying on single gene single protein companion diagnostics
  • She considers that regulatory, economic, and cultural factors are hindering the innovation and resulting in the science way ahead of the clinical aspect of diagnostics
  • Diagnostic research is not as well funded as drug discovery
  • Biomarkers, the foundation for the new personalized medicine, should be at forefront Read the Tipping Point by Malcolm Gladwell
  • FDA is constrained by statutory mandates 

 

Eric Schadt

Pathos

 

  • Multiple companies trying to chase different components of precision medicine strategy including all the one involved in AI
  • He is helping companies creating those mindmaps, knowledge graphs, and create more predictive systems
  • Population screening into population groups will be using high dimensional genomic data to determine risk in various population groups however 60% of genomic data has no reported ancestry
  • He founded Sema4 but many of these companies are losing $$ on these genomic diagnostics
  • So the market is not monetizing properly
  • Barriers to progress: arbitrary evidence thresholds for payers, big variation across health care system, regulatory framework

 

Beat Childhood Cancer Consortium Giselle

 

  • Consortium of university doctors in pediatrics
  • They had a molecular tumor board to look at the omics data
  • Showed example of choroid plexus tumor success with multi precision meds vs std chemo
  • Challenges: understanding differences in genomics test (WES, NGS, transcriptome etc.
  • Precision medicine needs to be incorporated in med education.. Fellowships.. Residency
  • She spends hours with the insurance companies providing more and more evidence to justify reimbursements
  • She says getting that evidence is a challenged;  biomedical information needs to be better CURATED

 

Dr. Ezra Cohen, Tempest

 

  • HPV head and neck cancer, good prognosis, can use cituximab and radiation
  • $2 billion investment at Templest of AI driven algorithm to integrate all omics; used LLM models too

Dr. Janet Woodcock

 

  • Our theoretical problem with precision and personalized medicine is that we are trained to think of the average patient
  • ISPAT II trial a baysian trial; COVID was a platform trial
  • She said there should there be NIH sponsored trials on adaptive biomarker platform trials

This event will be covered by the LPBI Group on Twitter.  Follow on

@Pharma_BI

@StephenJWillia2

@Aviva1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine

Read Full Post »

Israeli vendor AISAP gained FDA clearance for its new AI-enabled, point-of-care ultrasound (POCUS) software platform, AISAP Cardio

Reporter: Aviva Lev-Ari, PhD, RN

FDA clears AI-powered POCUS platform for structural heart disease, heart failure

Read Full Post »

« Newer Posts - Older Posts »